Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Nephrology

Infection as a predictor and potential mediator of poor renal outcomes in rituximab-treated primary membranous nephropathy: a retrospective cohort analysis

  1. 1Department of Nephrology and Institute of Nephrology, Sichuan Provincial People’s Hospital, Sichuan Provincial Clinical Research Center for Kidney Diseases, Key Medical Laboratory of Precision Prevention and Treatment of Kidney Diseases, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072 China
  2. 2School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Abstract

Background: Rituximab is effective for primary membranous nephropathy (PMN), yet infectious complications remain a critical safety concern with poorly characterized risk factors and prognostic implications.

Methods: This retrospective study analyzed 88 biopsy-proven PMN patients receiving rituximab at a tertiary center from January to December 2022. Patients were categorized based on the occurrence of severe infection (necessitating hospitalization, intravenous antibiotics, or causing death) over 24 months. Primary outcomes included cumulative probabilities of complete remission (CR) and clinical remission (CR plus partial remission, PR).

Results: Infections occurred in 18 patients (20.5%), comprising 29 episodes (skin or soft tissue, respiratory, perirenal, and sepsis). Infected patients were older and presented with lower baseline serum albumin, higher urea, and reduced renin-angiotensin-aldosterone system blockade usage (all P < 0.05). At 24 months, the infection group demonstrated markedly inferior outcomes: complete remission rate 11.1% versus 38.6% (P = 0.0537, not significant), overall clinical remission rate 61.1% versus 84.3% (Fisher’s exact P = 0.0467; χ² P = 0.0648, not significant), cumulative first-response rate 72.2% versus 95.7%, and delayed median time to remission (12 versus 3 months, P = 0.0004). Infected patients exhibited persistently worse renal function (lower eGFR) throughout follow-up (P < 0.05). Multivariate analysis identified age (odds ratio 1.054 per year [95% CI: 1.005–1.105], P = 0.030), serum albumin (odds ratio 0.880 per g/L increase [0.801–0.967], P = 0.008), and treatment-naïve status (odds ratio 0.155 [0.029–0.821], P = 0.028) as independent predictors. Baseline albumin predicted infection (AUC 0.696 [95% CI: 0.534–0.833 by bootstrap, B = 1,000]); the Youden optimal cutoff was approximately 21.0 g/L (sensitivity 0.611, specificity 0.814). In multivariate Cox regression adjusting for confounders, infection status remained independently associated with delayed remission (HR 0.33 [0.17–0.67], P = 0.002). After 1:2 propensity score matching, the 24-month remission rate was 76.5% in the infection group versus 97.1% in the non-infection group (log-rank P = 0.007). Time-dependent Cox analysis treating infection as a time-varying exposure yielded a hazard ratio of 0.20 (95% CI 0.08–0.51, P = 0.001) for clinical remission after infection occurrence.

Conclusions: Infections during rituximab therapy for PMN profoundly compromise treatment efficacy and renal outcomes. Baseline hypoalbuminemia and advanced age independently predict infection risk, while albumin level provides a candidate stratification aid warranting prospective validation. These findings support the rationale for risk-adapted monitoring and prophylactic strategies to optimize rituximab safety in PMN.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05281-6.

Related

  1. Association between triglyceride-glucose index and treatment response in primary membranous nephropathy: a retrospective cohort study
    Wei Chen, Tan Hou, Weimin Yu
    Renal FailurePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Efficacy and influencing factors of rituximab in idiopathic membranous nephropathy : A real-world retrospective study
    Xiaofei Xu, Qiwei Zhou, Subo Li +2
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMCEurope PMC
  3. Influence of Occupational Exposures on Cytokine Profiles in Patients with Membranous Nephropathy
    Maxime Teisseyre, Mounir El Mai, Marion Cremoni +1
    Kidney international reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMCEurope PMCPMC
  4. A case of recurrent membranous nephropathy with multiple necrotizing pulmonary nodules
    Zeng Wei-ling, Zhou Xian-ke, Du Dan-dan +5
    Linchuang shenzangbing zazhiPeer-reviewedCC BY-NC-NDFull textGeneral medicineDOAJ
  5. Sustained remission of NELL-1-positive membranous nephropathy after lung adenocarcinoma resection and during subsequent atezolizumab therapy in a 68-year-old man: a case report
    Masafumi Ikezawa, Yasuyuki Ikezawa, Mina Eguchi +8
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
BibTeX
@article{chen2026infection,
  title = {{Infection as a predictor and potential mediator of poor renal outcomes in rituximab-treated primary membranous nephropathy: a retrospective cohort analysis}},
  author = {Shasha Chen and Menglian Ma and Ping Guo and Guisen Li and Wei Wang},
  journal = {BMC Nephrology},
  year = {2026},
  month = aug,
  doi = {10.1186/s12882-026-05281-6},
  url = {https://doi.org/10.1186/s12882-026-05281-6},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Infection as a predictor and potential mediator of poor renal outcomes in rituximab-treated primary membranous nephropathy: a retrospective cohort analysis
AU  - Shasha Chen
AU  - Menglian Ma
AU  - Ping Guo
AU  - Guisen Li
AU  - Wei Wang
PY  - 2026
DA  - 2026/08/17
JO  - BMC Nephrology
DO  - 10.1186/s12882-026-05281-6
UR  - https://doi.org/10.1186/s12882-026-05281-6
AB  - Background: Rituximab is effective for primary membranous nephropathy (PMN), yet infectious complications remain a critical safety concern with poorly characterized risk factors and prognostic implications.  Methods: This retrospective study analyzed 88 biopsy-proven PMN patients receiving rituximab at a tertiary center from January to December 2022. Patients were categorized based on the occurrence of severe infection (necessitating hospitalization, intravenous antibiotics, or causing death) over 24 months. Primary outcomes included cumulative probabilities of complete remission (CR) and clinical remission (CR plus partial remission, PR).  Results: Infections occurred in 18 patients (20.5%), comprising 29 episodes (skin or soft tissue, respiratory, perirenal, and sepsis). Infected patients were older and presented with lower baseline serum albumin, higher urea, and reduced renin-angiotensin-aldosterone system blockade usage (all P < 0.05). At 24 months, the infection group demonstrated markedly inferior outcomes: complete remission rate 11.1% versus 38.6% (P = 0.0537, not significant), overall clinical remission rate 61.1% versus 84.3% (Fisher’s exact P = 0.0467; χ² P = 0.0648, not significant), cumulative first-response rate 72.2% versus 95.7%, and delayed median time to remission (12 versus 3 months, P = 0.0004). Infected patients exhibited persistently worse renal function (lower eGFR) throughout follow-up (P < 0.05). Multivariate analysis identified age (odds ratio 1.054 per year [95% CI: 1.005–1.105], P = 0.030), serum albumin (odds ratio 0.880 per g/L increase [0.801–0.967], P = 0.008), and treatment-naïve status (odds ratio 0.155 [0.029–0.821], P = 0.028) as independent predictors. Baseline albumin predicted infection (AUC 0.696 [95% CI: 0.534–0.833 by bootstrap, B = 1,000]); the Youden optimal cutoff was approximately 21.0 g/L (sensitivity 0.611, specificity 0.814). In multivariate Cox regression adjusting for confounders, infection status remained independently associated with delayed remission (HR 0.33 [0.17–0.67], P = 0.002). After 1:2 propensity score matching, the 24-month remission rate was 76.5% in the infection group versus 97.1% in the non-infection group (log-rank P = 0.007). Time-dependent Cox analysis treating infection as a time-varying exposure yielded a hazard ratio of 0.20 (95% CI 0.08–0.51, P = 0.001) for clinical remission after infection occurrence.  Conclusions: Infections during rituximab therapy for PMN profoundly compromise treatment efficacy and renal outcomes. Baseline hypoalbuminemia and advanced age independently predict infection risk, while albumin level provides a candidate stratification aid warranting prospective validation. These findings support the rationale for risk-adapted monitoring and prophylactic strategies to optimize rituximab safety in PMN.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05281-6.
SN  - 1471-2369
ER  -